In a report released today, David Bailey from Macquarie maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$321.00. The company’s shares closed last Friday at $152.64.
According to TipRanks, Bailey is an analyst with an average return of -12.2% and a 26.92% success rate.
CSL has an analyst consensus of Strong Buy, with a price target consensus of $205.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $217.82 and a one-year low of $148.55. Currently, CSL has an average volume of 1,114.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CMXHF in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CSL (CMXHF) Company Description:
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.
